How are energy investors positioned?
LifeMD , Inc. (NASDAQ:LFMD) recently saw its Chief Executive Officer, Justin Schreiber, sell a significant portion of his holdings in the company. According to a recent SEC filing, Schreiber sold 50,000 shares of LifeMD’s common stock on February 14, 2025. The shares were sold at an average price of $7.5524 each, totaling approximately $377,620. The sale comes as the company demonstrates strong operational performance, with impressive revenue growth of 42% and industry-leading gross margins of nearly 90%, according to InvestingPro data.
Following this transaction, Schreiber holds 2,653,715 shares indirectly through Schreiber Holdings LLC, and an additional 200,000 shares directly. The sale was executed under a prearranged trading plan, indicating a strategic decision to liquidate a portion of his holdings. The stock has seen significant volatility recently, with a 28% decline over the past week, though InvestingPro analysis suggests the company maintains a GREAT financial health score.
This transaction provides insight into the trading activities of LifeMD’s top executive, offering investors a glimpse into the leadership’s approach to managing their equity in the company. According to InvestingPro analysis, the stock currently appears undervalued, with additional insights available through their comprehensive Pro Research Report, which covers over 1,400 US stocks.
In other recent news, LifeMD reported a 38% increase in revenue during the third quarter, reaching $53.4 million, with a significant improvement in gross margin to 90.6% from 87.6% the previous year. Additionally, the number of active telehealth subscribers increased by 30% to approximately 269,000. Meanwhile, Lake Street Capital Markets initiated coverage of LifeMD with a Buy rating and a price target of $12, citing the company’s rapid growth and strategic direction in the virtual healthcare market. However, Mizuho (NYSE:MFG) initiated coverage with a Neutral rating and a price target of $7, highlighting concerns about the sustainability of LifeMD’s subscription revenue, particularly from GLP-1 drug compounding. Despite this, Mizuho anticipates significant growth in LifeMD’s revenue, projecting that over half will come from weight management programs by 2026. In another development, LifeMD announced that CEO Justin Schreiber’s salary would increase to $500,000 in 2025 following an amendment to his employment agreement. These recent developments indicate active expansion and strategic adjustments within LifeMD.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.